WASHINGTON, Aug 5 — The United States government will pay Johnson & Johnson over US$1 billion (RM4.2 billion) for 100 million doses of its potential coronavirus vaccine, as it stocks up on vaccine and drugs in an attempt to tame the pandemic.
The latest contract is priced at roughly US$10 per vaccine dose produced by J&J, or around US$14.50 per dose, including a previous US$456 million the US government promised to J&J for vaccine development in March. That compares with the US$19.50 per dose that the US is paying for the vaccine being developed by Pfizer Inc and German biotech BioNTech SE.
J&J is studying both one and two-dose regimens of its vaccine. Pfizer and BioNTech’s candidate would require two doses per person treated.
The drugmaker said today it would deliver the vaccine to the Biomedical Advanced Research and Development Authority (BARDA) on a not-for-profit basis to be used after approval or emergency use authorisation by the US Food and Drug Administration (FDA).
The US government may also purchase an additional 200 million doses under a subsequent agreement. J&J did not disclose that deal’s value.
As the race for vaccines and treatments for Covid-19 intensifies, the US government has been signing deals to buy them through its Operation Warp Speed programme. Other drugmakers who have signed deals include Sanofi SA and Regeneron Inc.
This is J&J’s first deal to supply its investigational vaccine to a country. Talks are underway with the European Union, but no deal has yet been reached.
J&J’s investigational vaccine is currently being tested on healthy volunteers in the United States and Belgium in an early-stage study.
There are currently no approved vaccines for Covid-19. More than 20 are in clinical trials.
Shares of J&J were up around one per cent in early trading on the New York Stock Exchange. — Reuters
